Myeloid Leukaemia
![Myeloid Leukaemia Myeloid Leukaemia](/media/9242/arrowe_park_entrance_blur1.jpg?anchor=center&mode=crop&width=816&height=255&rnd=131770972340000000&quality=100)
PROPEL
What is the study about?
Treatment for Acute Myeloid Leukaemia (AML) and Myelodysplastic syndrome with excess blasts (MDS-EB2) is extremely challenging and patients often feel very tired (fatigued) have low mood, poor nutrition and be unable to do any exercise. Programmes that help patients improve their overall health and fitness before major treatment is called prehabilitation. This study aims to see if a personalised prehabilitation package which includes remote support for emotional wellbeing, nutrition and exercise can help patients get through all cycles of intensive chemotherapy and stem cell transplant (if given), as well as reduce tiredness, improve quality of life, and treatment outcomes for patients with AML and MDS-EB2.
Who can take part?
People who have been diagnosed with AML or MDS with excess blasts and are, or their blood results suggest they are likely to be in remission after induction chemotherapy. They will also be planning to undertake consolidation chemotherapy with or without a stem cell transplant.
How do I take part?
Please ask at your next clinic appointment.